Skip to main content
ALTERITY THERAPEUTICS LTD logo

ALTERITY THERAPEUTICS LTD — Investor Relations & Filings

Ticker · ATHE ISIN · US7397272045 US Manufacturing
Filings indexed 1,023 across all filing types
Latest filing 2026-05-19 Foreign Filer Report
Country US United States of America
Listing US ATHE

About ALTERITY THERAPEUTICS LTD

https://alteritytherapeutics.com/

Alterity Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases. The company's lead drug candidate, ATH434, is a first-in-class small molecule designed to address the underlying pathology of these conditions by inhibiting the aggregation of pathological proteins. ATH434 is being evaluated in clinical trials for the treatment of Parkinsonian disorders, including Multiple System Atrophy (MSA). The company's therapeutic approach aims to modify the course of disease rather than merely treating symptoms. In addition to its lead program, Alterity Therapeutics maintains a drug discovery platform to generate new therapeutic candidates for a range of neurodegenerative diseases.

Recent filings

Filing Released Lang Actions
FORM 6-K
Foreign Filer Report
2026-05-19 English
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
Foreign Filer Report
2026-05-12 English
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
Foreign Filer Report
2026-05-11 English
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
Foreign Filer Report
2026-05-07 English
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
Foreign Filer Report
2026-04-30 English
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
Foreign Filer Report
2026-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.